Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Rajanahally, Saneal ^a,b   Agno, Julio E ^a   Nalam, Roopa L ^a   Weinstein, Michael B ^c   Loveland, Kate L ^d   Matzuk, Martin M ^a   Li, Qinglei ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RICE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; INHIBIN A; SMAD2 PROTEIN; INHIBIN; SMAD2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GRANULOSA CELL; KNOCKOUT MOUSE; LIVER; MORTALITY; MOUSE; NONHUMAN; OVARY TUMOR; PATHOGENESIS; PROTEIN DEFICIENCY; STOMACH; SURVIVAL RATE; TISSUE LEVEL; TUMOR GROWTH; TUMOR PROMOTION; WASTING SYNDROME; WEIGHT REDUCTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; CARCINOMA; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TESTIS TUMOR;

MUS;

ACTIVINS; ANIMALS; CARCINOMA; FEMALE; INHIBINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; SMAD2 PROTEIN; TESTICULAR NEOPLASMS;

EID: 77953668555     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-69     Document Type: Article

References (60)

1. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647. 10.1126/science.1071809, 12040180.
2. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002, 23:787-823. 10.1210/er.2002-0003, 12466190.
3. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996, 6:432-438. 10.1016/S0959-437X(96)80064-5, 8791534.
4. Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R. A homodimer of the beta-subunits of inhibin A stimulates the secretion of pituitary follicle stimulating hormone. Biochem Biophys Res Commun 1986, 138:1129-1137. 10.1016/S0006-291X(86)80400-4, 3092817.
5. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986, 321:776-779. 10.1038/321776a0, 3012369.
6. Xu J, McKeehan K, Matsuzaki K, McKeehan WL. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Biol Chem 1995, 270:6308-6313. 10.1074/jbc.270.11.6308, 7890768.
7. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75:671-680. 10.1016/0092-8674(93)90488-C, 8242742.
8. Massague J. Receptors for the TGF-beta family. Cell 1992, 69:1067-1070. 10.1016/0092-8674(92)90627-O, 1319842.
9. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A. Functional analysis of activins during mammalian development. Nature 1995, 374:354-356. 10.1038/374354a0, 7885473.
10. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791. 10.1146/annurev.biochem.67.1.753, 9759503.
11. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol 2009, 202:1-12. 10.1677/JOE-08-0549, 19273500.
12. Kaivo-oja N, Jeffery LA, Ritvos O, Mottershead DG. Smad signalling in the ovary. Reprod Biol Endocrinol 2006, 4:21. 10.1186/1477-7827-4-21, 1459162, 16611366.
13. Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006, 132:191-206. 10.1530/rep.1.01074, 16885529.
14. Mehra A, Wrana JL. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol 2002, 80:605-622. 10.1139/o02-161, 12440701.
15. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci 2001, 114:4359-4369.
16. Ying SY. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 1988, 9:267-293. 10.1210/edrv-9-2-267, 3136011.
17. De Jong FH. Inhibin. Physiol Rev 1988, 68:555-607.
18. Arora DS, Cooke IE, Ganesan TS, Ramsdale J, Manek S, Charnock FM, Groome NP, Wells M. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary. J Pathol 1997, 181:413-418. 10.1002/(SICI)1096-9896(199704)181:4<413::AID-PATH789>3.0.CO;2-U, 9196439.
19. Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996, 137:486-494. 10.1210/en.137.2.486, 8593793.
20. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 2005, 3:50-61.
21. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319. 10.1038/360313a0, 1448148.
22. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996, 10:534-543. 10.1210/me.10.5.534, 8732684.
23. Li Q, Karam SM, Coerver KA, Matzuk MM, Gordon JI. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial lineages. Mol Endocrinol 1998, 12:181-192. 10.1210/me.12.2.181, 9482661.
24. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994, 91:8817-8821. 10.1073/pnas.91.19.8817, 44697, 8090730.
25. Burns KH, Agno JE, Chen L, Haupt B, Ogbonna SC, Korach KS, Matzuk MM. Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. Mol Endocrinol 2003, 17:2039-2052. 10.1210/me.2003-0039, 12855748.
26. Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, Finegold MJ. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 1996, 51:123-154.
27. Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol 1994, 8:983-995. 10.1210/me.8.8.983, 7997239.
28. Li Q, Graff JM, O'Connor AE, Loveland KL, Matzuk MM. SMAD3 regulates gonadal tumorigenesis. Mol Endocrinol 2007, 21:2472-2486. 10.1210/me.2007-0147, 17595316.
29. Trudeau VL, Matzuk MM, Hache RJ, Renaud LP. Overexpression of activin-beta A subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of alpha-inhibin deficient mice. Biochem Biophys Res Commun 1994, 203:105-112. 10.1006/bbrc.1994.2155, 8074643.
30. Cipriano SC, Chen L, Kumar TR, Matzuk MM. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 2000, 141:2319-2327. 10.1210/en.141.7.2319, 10875231.
31. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990, 247:836-838. 10.1126/science.2106159, 2106159.
32. Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod 2007, 13:675-683. 10.1093/molehr/gam055, 17704537.
33. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998, 393:786-790. 10.1038/31693, 9655392.
34. Heyer J, Escalante-Alcalde D, Lia M, Boettinger E, Edelmann W, Stewart CL, Kucherlapati R. Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc Natl Acad Sci USA 1999, 96:12595-12600. 10.1073/pnas.96.22.12595, 23005, 10535967.
35. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor Smad2. Proc Natl Acad Sci USA 1998, 95:9378-9383. 10.1073/pnas.95.16.9378, 21346, 9689088.
36. Liu Y, Festing M, Thompson JC, Hester M, Rankin S, El-Hodiri HM, Zorn AM, Weinstein M. Smad2 and Smad3 coordinately regulate craniofacial and endodermal development. Dev Biol 2004, 270:411-426. 10.1016/j.ydbio.2004.03.017, 15183723.
37. Liu Y, Festing MH, Hester M, Thompson JC, Weinstein M. Generation of novel conditional and hypomorphic alleles of the Smad2 gene. Genesis 2004, 40:118-123. 10.1002/gene.20072, 15452874.
38. Li Q, Pangas SA, Jorgez CJ, Graff JM, Weinstein M, Matzuk MM. Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells in vivo. Mol Cell Biol 2008, 28:7001-7011. 10.1128/MCB.00732-08, 2593383, 18809571.
39. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 2002, 32:408-410. 10.1038/ng1003, 12368913.
40. Kumar TR, Wang Y, Matzuk MM. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 1996, 137:4210-4216. 10.1210/en.137.10.4210, 8828479.
41. Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. J Endocrinol 1996, 148:267-279. 10.1677/joe.0.1480267, 8699141.
42. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod 1999, 14:827-832. 10.1093/humrep/14.3.827, 10221721.
43. Jorgez CJ, Klysik M, Jamin SP, Behringer RR, Matzuk MM. Granulosa cell-specific inactivation of follistatin causes female fertility defects. Mol Endocrinol 2004, 18:953-967. 10.1210/me.2003-0301, 14701941.
44. Pangas SA, Jorgez CJ, Tran M, Agno J, Li X, Brown CW, Kumar TR, Matzuk MM. Intraovarian activins are required for female fertility. Mol Endocrinol 2007, 21:2458-2471. 10.1210/me.2007-0146, 17609433.
45. Andreu-Vieyra C, Chen R, Matzuk MM. Effects of granulosa cell-specific deletion of Rb in Inha-{alpha} null female mice. Endocrinology 2007, 148:3837-3849. 10.1210/en.2006-1590, 17510234.
46. Andreu-Vieyra C, Chen R, Matzuk MM. Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure. Mol Endocrinol 2008, 22:2141-2161. 10.1210/me.2008-0033, 2631371, 18599617.
47. Pangas SA, Li X, Umans L, Zwijsen A, Huylebroeck D, Gutierrez C, Wang D, Martin JF, Jamin SP, Behringer RR, Robertson EJ, Matzuk MM. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008, 28:248-257. 10.1128/MCB.01404-07, 2223289, 17967875.
48. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005, 65:7968-7975.
49. Panopoulou E, Murphy C, Rasmussen H, Bagli E, Rofstad EK, Fotsis T. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res 2005, 65:1877-1886. 10.1158/0008-5472.CAN-04-2828, 15753386.
50. McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP. Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 1997, 154:535-545. 10.1677/joe.0.1540535, 9379131.
51. Yokomuro S, Tsuji H, Lunz JG, Sakamoto T, Ezure T, Murase N, Demetris AJ. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000, 32:26-35. 10.1053/jhep.2000.8535, 10869285.
52. Looyenga BD, Hammer GD. Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Mol Endocrinol 2007, 21:2440-2457. 10.1210/me.2006-0402, 17652186.
53. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998, 94:585-594. 10.1016/S0092-8674(00)81600-1, 9741623.
54. Dennler S, Huet S, Gauthier JM. A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 1999, 18:1643-1648. 10.1038/sj.onc.1202729, 10102636.
55. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000, 19:1745-1754. 10.1093/emboj/19.8.1745, 302010, 10775259.
56. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. Embo J 1998, 17:3091-3100. 10.1093/emboj/17.11.3091, 1170648, 9606191.
57. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998, 1:611-617. 10.1016/S1097-2765(00)80061-1, 9660945.
58. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, Mitchelson K, Cheng J, Zhou Y. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol 2008, 215:422-433. 10.1002/jcp.21325, 17960585.
59. Itman C, Small C, Griswold M, Nagaraja AK, Matzuk MM, Brown CW, Jans DA, Loveland KL. Developmentally regulated SMAD2 and SMAD3 utilization directs activin signaling outcomes. Dev Dyn 2009, 238:1688-1700. 10.1002/dvdy.21995, 19517569.
60. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007, 101:9-33. 10.1002/jcb.21255, 17340614.